Rei Kudo_MDPhD
@Reik0110
Breast surgery in Jikei University 🇯🇵→Research fellow in Memorial Sloan Kettering @Chandarlapatylab🇺🇸→ NCC @Yoshimilab🇯🇵
Delighted to share our research @Cancer_Cell @MSKCancerCenter ! We explore the mechanisms behind variable #BreastCancer responses to CDK4/6 inhibitors. TP53 mutation is linked to lack of long-term disease control. cell.com/cancer-cell/fu…
The human proteome and organ age clocks across the lifespan, a tour de force report @CellCellPress cell.com/cell/abstract/…
It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM @YJanjigianMD @ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.@OncoAlert @oncodaily nejm.org/doi/full/10.10…
下井先生！いつも勉強させていただいてます@shimoi_oncology
The Top Most Active Cancer Institutes that were leading the conversation during the @ASCO 2025, ranked based on oncologists' reactions and engagement on X. Follow us for more #ASCO25 updates: t.ly/7TCD6 #LARVOL #CancerResearch #Oncology #CancerData…
Pleased to share the first series of pts who experienced recurrence on adjuvant abemaciclib+ET: ➤ 9.2% (15/163) recurred ➤ 50% ER loss post-tx ➤ 90% TP53-pathway alterations post-tx ➤ Median 1L m+ tx duration: 3.0 mo (IQR 1.6–5.0) shorturl.at/ZnMI5
【論文発表】ゲノム生物学研究分野の研究成果が@eBioMedicineに掲載されました。多施設共同研究により、日本人女性を対象に乳がん・卵巣がんの大規模ゲノム解析を実施し、関連遺伝子の同定と生涯発症リスクの推定を行いました。(1/2) thelancet.com/journals/ebiom…
NEJMに同時発表のPROTACの初めてのPhase3試験のPositive result FULに対してのPFS改善に加えて、非常に有害事象が少ないことがとてもよさそう。 フロントラインのVERITAC-3は途中中止が残念。#ASCO25 われらの吉波哲大先生が著者に入っています！ Vepdegestrant, a PROTAC Estrogen Receptor…
VERITAC-2 trial. Vepdegestrant didn’t show PFS improvement in ITT population, but demonstrated statistically significant and clinically meaningful improvement in PFS vs fulvestrant in the ESR1m population. #ASCO25 mPFS in ESR1m 5.0 vs 2.1m (HR 0.57, p<0.001) Fatigue is the…
Very important Insight at #ASCO25 >10% of ER -/low breast cancer patients had increased ER expression in residual tumors post-NAC ✅Retesting can unlock adjuvant endocrine therapy. ⬇️Don’t skip it if there’s residual disease! meetings.asco.org/abstracts-pres… #Oncology @OncoAlert @ASCO
Impressive phase 2 data with the Trop2 ADC Sac-TMT for 1L mTNBC (n=41): ORR 70%, mPFS 13.4 months. High activity irrespective of PDL1 expression. Same setting of ASCENT-03/04. Confirms the feeling that, in the future, we’ll treat mTNBC with frontline Trop2 ADCs. #ASCO25
Learn more about this new study led by @MSKCancerCenter breast medical oncologist and Fred's Team runner, Dr. Sarat Chandarlapaty.
A new study in @NatureGenet from MSK's Dr. Sarat Chandarlapaty and colleagues investigates how APOBEC3 #mutagenesis drives therapy resistance in #BreastCancer. Learn more: go.nature.com/45kkqfg
Journal Club-84 @MolecularCell High-throughput analysis of ~700 transcription factor (TF) isoforms demonstrated the molecular functional diversification conferred by TF alternative isoforms. Furthermore, differences in IDR (intrinsically disordered regions) -flexible structural…
Excited to announce that our new paper is out! 🎉 Can AI evaluate the quality of medical information as accurately as humans? According to our study — Yes, it can, but expert input is still key. 私たちの新しい論文です！AIで医療情報の質は評価できるか？ link.springer.com/article/10.100…
A new study in @NatureGenet from MSK's Dr. Sarat Chandarlapaty and colleagues investigates how APOBEC3 #mutagenesis drives therapy resistance in #BreastCancer. Learn more: go.nature.com/45kkqfg
Next-gen CDK inhibitors in HR+/HER2− mBC: – Atirmociclib: 94% CBR, 59% ORR in 1L – PF-07104091 (CDK2i): PRs post-CDK4/6i – Combo shows 28% ORR in pretreated pts New hope beyond resistance! #ESMOBreast25 #ESMOAmbassadors @myESMO
🔹 1L: AI or Fulv + CDK4/6i 🔹 2L: • PI3K & ESR1 wt: Fulv + Everolimus / Abemaciclib • ESR1 mut: Elacestrant • PI3K mut: Fulv + Alpelisib / Capivasertib 🔹 3L+: Options incl. chemo, Elacestrant, Olaparib, T-DXd 🔹 4L+: SG, DATO-DXd, biomarkers @stolaney1 @oncodaily @myESMO
2025年F1®マイアミGPのドライバーズパレード。F1®ドライバーがレゴ ブロックで作られたマシンに乗って登場！ #F1jp #マイアミGP #その手でスリルを
What a surprise, PROTAC's verification of superiority of first-line therapy over endocrine therapy is so severe that it is being stopped early. What a sad announcement this is. annalsofoncology.org/article/S0923-…
Arvinas lays off 33% of staff and discontinues two phase 3 trials of 1L vepdegestrant+CDK4/6i and 1L vepdegestrant+CDK4i (atirmociclib). Further development of the PROTAC will focus on the 2L setting. fiercebiotech.com/biotech/arvina…
Based on AstraZeneca’s QCS for TROP2, Roche Diagnostics received FDA Breakthrough Device Designation (BDD) for the VENTANA TROP2 (EPR20043) RxDx assay! Nice spotlight presentation at #AACR25 roche.com/media/releases…
Dr. @marinagarassino at #WCLC24 Presidential Plenary presents Normalized Membrane Ratio of TROP2 as a biomarker for datopotamab deruxtecan in TROPION-Lung01 (Dato-DXd vs docetaxel in previously treated NSCLC which previously showed PFS benefit with Dato-DXd.
Once again excellent work by @AvanGupta showing that #APOBEC3 drives resistance causing mutations. #AACR25 10.1101/2024.04.29.591453 now in press @NatureGenet
How does a tumor acquire all those resistance promoting alterations in the first place? Kudos to @AvanGupta @MSKCancerCenter for defining the role of #APOBEC3 mutagenesis in this process. #SABCS24
Missed #SABCS24? Catch up now at #AACR25! First up: @PedramRazaviMD @MSKCancerCenter: how can we better predict response to #CDK4/6i+ #endocrinetherapy to better escalate/de-escalate therapies? #machinelearning incl clinical + genomic models (both together are better)
Expert talk on ctDNA by Stefania Morganti breast cancer- we need more data on what to do for pts with MRD in the adjuvant setting @StefiMorganti @DFCI_BreastOnc @VKaklamani